Editor's Note: This is a bonus story from Gary B. Smith, whose commentary usually appears only on

RealMoney

, where it was published today at 8:31 a.m. We're offering it today to

TheStreet.com

readers. To read Smith's commentary regularly, please click here for information about a free trial to

RealMoney.

Let me disclose right up front that I am long

Merck

(MRK) - Get Report

. Let me also disclose that I'm not happy about it!

The question on everyone's mind, however, is whether this latest drop is a buying opportunity. Some will argue that litigation will drag on, giving you a much lower entry price than you have now, and others will argue that Merck has more than enough cash reserves and that this is nothing more than

Altria

(MO) - Get Report

all over again.

As usual, I defer to the chart and there the story is clear: Right now the stock is just starting another leg down and surely not bottoming out. That makes buying Monday morning not risky, but stupid.

Just calling 'em as I see 'em, and remember that's from someone who owns the stock!

What's not stupid? Trying to pick the stock up in the $15 area.

Today, the

Dow Jones Industrial Average

,

Genentech

(DNA)

,

Micron Technology

(MU) - Get Report

,

Cobiz

(COBZ) - Get Report

,

Dominos Pizza

(DPZ) - Get Report

and

CAE

(CGT)

.

Charts produced by TC2000, which is a registered trademark of

Worden Brothers Inc.

And that is the final word from St. Elmo Avenue, where lately I've taken a shine to Quizno's subs. Yeah, there really is something about those toasted buns!

At the time of publication, Smith was long Merck, although holdings can change at any time.

Gary B. Smith is a freelance writer who trades for his own account from his Maryland home using technical analysis. Under no circumstances does the information in this column represent a recommendation to buy or sell stocks.

Smith writes a daily technical analysis column for RealMoney.com and also produces a daily premium product for TheStreet.com called The Chartman's Top Stocks --

click here for a free two-week trial. While Gary cannot provide investment advice or recommendations, he appreciates your feedback;

click here

to send him an email.